ticlopidine has been researched along with Chronic Kidney Failure in 37 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes." | 9.12 | Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007) |
| "The aim of the present study was to evaluate clopidogrel treatment after incident myocardial infarction (MI) in patients with and without chronic kidney disease (CKD)." | 7.80 | Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. ( Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C, 2014) |
| " The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes." | 5.12 | Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007) |
| "We estimated the effectiveness and safety of antiplatelet drugs (aspirin and clopidogrel) for the prevention of recurrent ischemic stroke in end-stage renal disease patients undergoing dialysis during long-term follow-up after first-time ischemic stroke." | 3.80 | Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis. ( Chen, CY; Huang, YB; Lai, WT; Lee, CT; Lee, KT, 2014) |
| "The aim of the present study was to evaluate clopidogrel treatment after incident myocardial infarction (MI) in patients with and without chronic kidney disease (CKD)." | 3.80 | Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. ( Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C, 2014) |
| " The study was performed in healthy subjects, patients with coronary artery disease, patients with end-stage renal disease, and patients with acute coronary syndrome after treatment with prasugrel or clopidogrel." | 3.76 | A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. ( Jakubowski, JA; Li, YG; Luo, J; Payne, CD; Small, DS; Tomlin, ME; Winters, KJ, 2010) |
| "In this single-center, prospective, randomized pharmacodynamic study, 52 ESRD patients on HD were prescribed clopidogrel (300mg loading dose [LD], then 75mg daily), standard-dose ticagrelor (180mg LD, then 90mg twice daily), or low-dose ticagrelor (90mg LD, then 90mg daily) for 14days." | 2.84 | The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. ( Ihm, CG; Jeong, KH; Kim, JB; Kim, JS; Kim, KS; Kim, W; Kim, WS; Lee, TW; Woo, JS, 2017) |
| "Also, 36 patients with chronic renal failure (60 +/- 5 years) were divided into 2 groups according to their daily dose of clopidogrel: a daily dose of 75 mg of clopidogrel for 30 days (group II, n = 18) or a daily dose of 150 mg (group III, n = 18)." | 2.74 | A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. ( Hwang, SH; Kang, WY; Kim, W; Park, CS; Park, SH, 2009) |
| "People with end-stage renal disease (ESRD) often require either the formation of an arteriovenous fistula (AVF) or an interposition prosthetic arteriovenous graft (AVG) for haemodialysis." | 2.72 | Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. ( Da Silva, A; Kamarizan, MFA; Mohamed, I, 2021) |
| "End-stage renal disease (ESRD) patients often require either the formation of an arteriovenous (AV) fistula or an AV interposition prosthetic shunt for haemodialysis." | 2.52 | Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. ( Da Silva, A; Tanner, NC, 2015) |
| "She developed aplastic anemia seven weeks after initiation of ticlopidine." | 2.41 | Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case report and literature review. ( Ammash, Z; Dabajah, B; Mourad, FH; Nasrallah, A; Taher, A, 2000) |
| "Clopidogrel and ticlopidine, sometimes in combination with ASA, are associated with a low risk of bleeding during renal transplantation and does not seem to be a contraindication for renal transplant surgery." | 1.40 | Ticlopidine and clopidogrel, sometimes combined with aspirin, only minimally increase the surgical risk in renal transplantation: a case-control study. ( Abramowicz, D; Benahmed, A; Broeders, N; Donckier, V; Ghisdal, L; Hoang, AD; Kianda, M; Le Moine, A; Lemy, A; Madhoun, P; Massart, A; Mikhalski, D; Racapé, J; Sadis, C; Wissing, M, 2014) |
| "Patients with ESRD are at higher risk for coronary artery disease (CAD) and also their post-interventional outcome is worse compared to patients with normal renal function." | 1.40 | Haemodialysis impairs clopidogrel but not aspirin responsiveness in patients with end-stage renal disease. Results of a pilot study. ( Bocksch, W; Fateh-Moghadam, S; Gawaz, M; Geisler, T; Htun, P; Kan, T; Mueller, E; Pohle, C; Schindler, R, 2014) |
| "Ticlopidine hydrochloride was administered at a dose of 200 mg daily for 4 weeks." | 1.31 | Effect of ticlopidine hydrochloride on erythropoietin-induced rise in blood pressure in patients on maintenance hemodialysis. ( Akai, Y; Ando, Y; Asano, Y; Furuya, H; Inoue, M; Kusano, E; Tabei, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.81) | 18.7374 |
| 1990's | 2 (5.41) | 18.2507 |
| 2000's | 13 (35.14) | 29.6817 |
| 2010's | 17 (45.95) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Mohamed, I | 1 |
| Kamarizan, MFA | 1 |
| Da Silva, A | 2 |
| Kim, JS | 1 |
| Woo, JS | 2 |
| Kim, JB | 2 |
| Kim, WS | 2 |
| Lee, TW | 2 |
| Kim, KS | 2 |
| Ihm, CG | 2 |
| Kim, W | 4 |
| Jeong, KH | 2 |
| Benahmed, A | 1 |
| Kianda, M | 1 |
| Ghisdal, L | 1 |
| Broeders, N | 1 |
| Massart, A | 1 |
| Lemy, A | 1 |
| Mikhalski, D | 1 |
| Hoang, AD | 1 |
| Donckier, V | 1 |
| Sadis, C | 1 |
| Le Moine, A | 1 |
| Madhoun, P | 1 |
| Racapé, J | 1 |
| Wissing, M | 1 |
| Abramowicz, D | 1 |
| Htun, P | 1 |
| Kan, T | 1 |
| Mueller, E | 1 |
| Pohle, C | 1 |
| Schindler, R | 1 |
| Geisler, T | 1 |
| Gawaz, M | 1 |
| Bocksch, W | 1 |
| Fateh-Moghadam, S | 1 |
| Chen, CY | 1 |
| Lee, KT | 1 |
| Lee, CT | 1 |
| Lai, WT | 1 |
| Huang, YB | 1 |
| Kakisis, JD | 1 |
| Vassilas, K | 1 |
| Antonopoulos, C | 1 |
| Sfyroeras, G | 1 |
| Moulakakis, K | 1 |
| Liapis, CD | 1 |
| Blicher, TM | 1 |
| Hommel, K | 1 |
| Kristensen, SL | 1 |
| Torp-Pedersen, C | 1 |
| Madsen, M | 1 |
| Kamper, AL | 1 |
| Olesen, JB | 1 |
| Williams, JM | 1 |
| Tuttle-Newhall, JE | 1 |
| Schnitzler, M | 1 |
| Dzebisashvili, N | 1 |
| Xiao, H | 1 |
| Axelrod, D | 1 |
| Mogal, H | 1 |
| Lentine, KL | 1 |
| Cho, JH | 1 |
| Bouatou, Y | 1 |
| Samer, CF | 1 |
| Fontana, P | 1 |
| Daali, Y | 1 |
| Desmeules, J | 1 |
| Tanner, NC | 1 |
| Lee, JY | 1 |
| Moon, IT | 1 |
| Lee, HY | 1 |
| Lee, HL | 1 |
| Han, DS | 1 |
| Chen, YT | 1 |
| Chen, HT | 1 |
| Hsu, CY | 1 |
| Chao, PW | 1 |
| Kuo, SC | 1 |
| Ou, SM | 1 |
| Shih, CJ | 1 |
| Chan, KE | 1 |
| Lazarus, JM | 1 |
| Thadhani, R | 1 |
| Hakim, RM | 1 |
| Kittisupamongkol, W | 1 |
| Park, SH | 1 |
| Park, CS | 1 |
| Kang, WY | 1 |
| Hwang, SH | 1 |
| Mousa, SA | 1 |
| Jeske, WP | 1 |
| Fareed, J | 1 |
| Jakubowski, JA | 1 |
| Li, YG | 1 |
| Small, DS | 1 |
| Payne, CD | 1 |
| Tomlin, ME | 1 |
| Luo, J | 1 |
| Winters, KJ | 1 |
| Ponikowski, P | 1 |
| Ronco, C | 1 |
| Anker, SD | 1 |
| Geara, AS | 1 |
| Ayoub, I | 1 |
| Abi Rached, J | 1 |
| Siddique, MN | 1 |
| Ghimire, P | 1 |
| El-Sayegh, S | 1 |
| Alexopoulos, D | 1 |
| Xanthopoulou, I | 1 |
| Plakomyti, TE | 1 |
| Goudas, P | 1 |
| Koutroulia, E | 1 |
| Goumenos, D | 1 |
| Kusano, E | 1 |
| Inoue, M | 1 |
| Akai, Y | 1 |
| Furuya, H | 1 |
| Ando, Y | 1 |
| Tabei, K | 1 |
| Asano, Y | 1 |
| Kaufman, JS | 1 |
| O'Connor, TZ | 1 |
| Zhang, JH | 1 |
| Cronin, RE | 1 |
| Fiore, LD | 1 |
| Ganz, MB | 1 |
| Goldfarb, DS | 1 |
| Peduzzi, PN | 1 |
| Igaki, N | 1 |
| Matsuda, T | 1 |
| Yatani, H | 1 |
| Kawaguchi, T | 1 |
| Kida, A | 1 |
| Yanase, K | 1 |
| Moriguchi, R | 1 |
| Sakai, M | 1 |
| Tamada, F | 1 |
| Goto, T | 1 |
| Akcay, A | 1 |
| Kanbay, M | 1 |
| Agca, E | 1 |
| Sezer, S | 1 |
| Ozdemir, FN | 1 |
| Janicki, K | 1 |
| Bojarska-Szmygin, A | 1 |
| Pietura, R | 1 |
| Janicka, L | 1 |
| Suh, SY | 1 |
| Rha, SW | 1 |
| Kim, JW | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Oh, DJ | 1 |
| Ro, YM | 1 |
| Gruberg, L | 1 |
| Beyar, R | 1 |
| Keltai, M | 1 |
| Tonelli, M | 1 |
| Mann, JF | 1 |
| Sitkei, E | 1 |
| Lewis, BS | 1 |
| Hawken, S | 1 |
| Mehta, SR | 1 |
| Yusuf, S | 1 |
| Mambelli, E | 1 |
| Mancini, E | 1 |
| Casanova, S | 1 |
| Di Felice, A | 1 |
| Santoro, A | 1 |
| Méndez Martín, A | 1 |
| Ortiz González, A | 1 |
| Gutiérrez González, JR | 1 |
| Kobayashi, K | 1 |
| Maeda, K | 1 |
| Koshikawa, S | 1 |
| Kawaguchi, Y | 1 |
| Shimizu, N | 1 |
| Naito, C | 1 |
| Windus, DW | 1 |
| Santoro, SA | 1 |
| Atkinson, R | 1 |
| Royal, HD | 1 |
| Kamper, AM | 1 |
| Lins, RL | 1 |
| Zachée, P | 1 |
| Van Bergen, S | 1 |
| Hosten, S | 1 |
| Daelemans, R | 1 |
| Taher, A | 1 |
| Ammash, Z | 1 |
| Dabajah, B | 1 |
| Nasrallah, A | 1 |
| Mourad, FH | 1 |
| Griffanti-Bartoli, F | 1 |
| Altomonte, F | 1 |
| Pitton, L | 1 |
| Armani, U | 1 |
| Piana, A | 1 |
| Traietti, P | 1 |
| Chiappini, MG | 1 |
| Belfiglio, A | 1 |
| Bartoli, R | 1 |
| Bologna, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency[NCT00067119] | Phase 3 | 649 participants (Actual) | Interventional | 2003-01-01 | Completed | ||
| Impact of Vitamin D on Arteriovenous Fistulae Maturation Among ESRD Patients[NCT00912782] | 52 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Graft Creation in Patients With Chronic Kidney Disease[NCT01001351] | Phase 1/Phase 2 | 89 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel[NCT01328470] | Phase 4 | 85 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Maturation of an AVF is the ability to stick the AVF with two large bore needles at ≥ 6 consecutive dialysis sessions, and achievement of an AVF blood flow >300 ml/min, assessed at six months following AVF creation. (NCT00912782)
Timeframe: 6 months
| Intervention | percentage of group (Number) |
|---|---|
| Placebo | 50 |
| Cholecalciferol | 40 |
(NCT00912782)
Timeframe: 10 weeks
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Serum 25 (OH) D | Serum Calcium | |
| Cholecalciferol | 53.4 | 8.8 |
| Placebo | 18.4 | 9.1 |
6 reviews available for ticlopidine and Chronic Kidney Failure
| Article | Year |
|---|---|
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Wandering stent within the pulmonary circulation.
Topics: Aged, 80 and over; Angiography, Digital Subtraction; Anticoagulants; Arteriovenous Shunt, Surgical; | 2014 |
Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review.
Topics: Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Humans; Kidney Failure, Chronic; Platelet | 2015 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Humans; Kidney Failure, Chronic; Platelet Agg | 2015 |
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topi | 2010 |
Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case report and literature review.
Topics: Aged; Aged, 80 and over; Anemia, Aplastic; Aspirin; Bone Marrow Cells; Coronary Disease; Female; Gas | 2000 |
7 trials available for ticlopidine and Chronic Kidney Failure
| Article | Year |
|---|---|
The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis.
Topics: Adenosine; Adult; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Kidney Failur | 2017 |
Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study.
Topics: Adenosine; Adult; Aspirin; Clopidogrel; Cross-Over Studies; Drug Therapy, Combination; Female; Human | 2015 |
A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure.
Topics: Analysis of Variance; Clopidogrel; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Kid | 2009 |
A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure.
Topics: Analysis of Variance; Clopidogrel; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Kid | 2009 |
A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure.
Topics: Analysis of Variance; Clopidogrel; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Kid | 2009 |
A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure.
Topics: Analysis of Variance; Clopidogrel; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Kid | 2009 |
Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis.
Topics: Aged; Aspirin; Catheters, Indwelling; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; F | 2003 |
Preventive effects of Ticlopidine on the incidence of late A-V fistula thrombosis complications in haemodialyses patients.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Drug Administration Schedule; Female; Follow-Up Studies; | 2003 |
Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.
Topics: Aged; Angina, Unstable; Clopidogrel; Coronary Disease; Creatinine; Double-Blind Method; Female; Glom | 2007 |
Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients.
Topics: Drug Combinations; Humans; Kidney Failure, Chronic; Nadroparin; Platelet Aggregation Inhibitors; Ren | 1997 |
24 other studies available for ticlopidine and Chronic Kidney Failure
| Article | Year |
|---|---|
Ticlopidine and clopidogrel, sometimes combined with aspirin, only minimally increase the surgical risk in renal transplantation: a case-control study.
Topics: Aspirin; Blood Loss, Surgical; Case-Control Studies; Clopidogrel; Dose-Response Relationship, Drug; | 2014 |
Haemodialysis impairs clopidogrel but not aspirin responsiveness in patients with end-stage renal disease. Results of a pilot study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Hum | 2014 |
Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate | 2014 |
Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Cohort Studies; | 2014 |
Clopidogrel use as a risk factor for poor outcomes after kidney transplantation.
Topics: Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; G | 2014 |
Successful Management of Recurrent Colon Ulcer in Hemodialysis Patient after Conversion to Peritoneal Dialysis.
Topics: Aspirin; Colon; Colonic Diseases; Colonoscopy; Drug Therapy, Combination; Gastrointestinal Hemorrhag | 2015 |
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Ther | 2017 |
Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients.
Topics: Aged; Anticoagulants; Clopidogrel; Cohort Studies; Confidence Intervals; Female; Humans; Internation | 2009 |
Clopidogrel in ESRD patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Kidney Failure, Chronic; Platelet | 2009 |
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Clinical Trials as Topic; Clopidogrel; | 2010 |
Cardiorenal syndromes--recommendations from clinical practice guidelines: the cardiologist's view.
Topics: Acute Disease; Acute Kidney Injury; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhib | 2010 |
Does hemodialysis affect clopidogrel resistance as measured by VerifyNow P2Y12 test?
Topics: Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Drug Resistance; Humans; Kidney Failur | 2011 |
Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis.
Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Resistance; Female; Humans; K | 2012 |
Effect of ticlopidine hydrochloride on erythropoietin-induced rise in blood pressure in patients on maintenance hemodialysis.
Topics: Adult; Blood Pressure; Erythropoietin; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; | 2002 |
Deep venous thrombosis, myocardial infarction, and occlusion of vascular access associated with heparin-induced thrombocytopenia in a diabetic hemodialysis patient.
Topics: Anticoagulants; Catheters, Indwelling; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fi | 2003 |
Neutropenia due to clopidogrel in a patient with end-stage renal disease.
Topics: Adult; Clopidogrel; Humans; Kidney Failure, Chronic; Male; Neutropenia; Platelet Aggregation Inhibit | 2004 |
Neutropenia associated with clopidogrel use in a patient with chronic renal failure who underwent percutaneous coronary and peripheral intervention.
Topics: Adult; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Clopidogrel; Fatal Outcome; Female; Gra | 2006 |
End-stage renal disease and drug-eluting stents: one small step forward.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Coronary Restenosis; Humans; I | 2006 |
Severe ticlopidine-induced cholestatic syndrome.
Topics: Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Humans; Kidney Failure, Chronic; | 2007 |
[Changes in arterial blood gases after hemodialysis and the influence of platelet antiaggregation].
Topics: Adult; Blood Gas Analysis; Carbon Dioxide; Female; Humans; Kidney Failure, Chronic; Male; Middle Age | 1984 |
Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis--a multicenter collaborative double blind study.
Topics: Adult; Aged; Blood Urea Nitrogen; Chlorides; Creatinine; Double-Blind Method; Female; Fibrinolytic A | 1980 |
Effects of antiplatelet drugs on dialysis-associated platelet deposition in polytetrafluoroethylene grafts.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Vessel Prosthesis; Humans; Indium Radioisotopes; Kidne | 1997 |
[Use of a new platelet aggregation inhibitor, ticlopidine, in hemodialysis].
Topics: Adult; Aged; Blood Coagulation Disorders; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged | 1979 |
[Effects of the treatment with ticlopidine in hemodialyzed patients].
Topics: Heparin; Humans; Kidney Failure, Chronic; Platelet Aggregation; Platelet Aggregation Inhibitors; Ren | 1988 |